707
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Pharmacogenomics: Where does Britain Stand?

Pages 1-3 | Published online: 19 Dec 2011

References

  • Shih T , VourvahisM, SinghM, PapayJ. Pharmacogenetics: from bench science to the bedside. Drug Inf. J.42(5) , 503–513 (2008).
  • Zaza G , GranataS, SallustioF, GrandalianoG, SchenaFP. Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin. Exp. Immunol.159(3) , 268–280 (2010).
  • Vijverberg SJH , PietersT, CornelMC. Ethical and social issues in pharmacogenomics testing. Curr. Pharm. Des.16(2) , 245–252 (2010).
  • Ibarreta D , EllesR, CassimanJJ et al. Towards quality assurance and harmonization of genetic testing services in the European Union. Nature Biotechnol. 22(10) , 1230–1235 (2004).
  • Hudson J , OrviskaM. European attitudes to gene therapy and pharmacogenetics. Drug Discov. Today16(19–20) , 843–847 (2011).
  • Dati F , DenoyalG, van Helden J. European performance evaluations of the ADVIA Centaur infectious disease assays: requirements for performance evaluation according to the European directive on in vitro diagnostics. J. Clin. Virol.30(1) , S6–S10 (2004).
  • Kuzma J , NajmaieP, LarsonJ. Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms. J. Law Med. Ethics37(4) , 546–586 (2009).
  • Gaisser S , Vignola-GagneE, HusingB et al. EU policies in personalized medicine-related technologies. Pers. Med. 6(1) , 93–102 (2007).
  • Salerno RA , LeskoLJ. Pharmacogenomics in drug development and regulatory decision making: The Genomic Data Submission (GDS) Proposal. Pharmacogenomics5(1) , 25–30 (2004).
  • Gurwitz D , ZikaE, HopkinsMM et al. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12(3) , 134–141 (2009).
  • Hopkins MM , MahdiS, PatelP et al. DNA patenting: the end of an era? Nature Biotechnol. 25(2) , 185–187 (2007).
  • Paci D , HopkinsMM, ZikaE et al. Impact of DNA patents on pharmacogenomics research and development. Economic and Policy Issues 71(8) , 485–491 (2010).
  • Chen HY , ChenLC. Implementation of innovative pharmacogenetic tests into practice in Taiwan: an institutional perspective. Drug Dev. Res.71(8) , 502–506 (2010).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.